Skin innate immune response against fungal infections and the potential role of trained immunity

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2024
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
BOMBASSARO, Amanda
FIGUEIREDO, Julia Marcondes
JOOSTEN, Leo A. B.
VICENTE, Vania A.
QUEIROZ-TELLES, Flavio
MEIS, Jacques F.
KISCHKEL, Brenda
Citação
MYCOSES, v.67, n.1, article ID e13682, 11p, 2024
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Fungal skin infections are distributed worldwide and can be associated with economic and social traits. The immune response related to skin cells is complex and its understanding is essential to the comprehension of each cell's role and the discovery of treatment alternatives. The first studies of trained immunity (TI) described the ability of monocytes, macrophages and natural killer (NK) cells to develop a memory-like response. However, the duration of TI does not reflect the shorter lifespan of these cells. These conclusions supported later studies showing that TI can be observed in stem and haematopoietic cells and, more recently, also in non-immune skin cells such as fibroblasts, highlighting the importance of resident cells in response to skin disorders. Besides, the participation of less studied proinflammatory cytokines in the skin immune response, such as IL-36 gamma, shed light into a new possibility of inflammatory pathway blockade by drugs. In this review, we will discuss the skin immune response associated with fungal infections, the role of TI in skin and clinical evidence supporting opportunities and challenges of TI and other inflammatory responses in the pathogenesis of fungal skin infections.
Palavras-chave
fungal skin infections, immune response, proinflammatory cytokines, tissue inflammation, trained immunity
URI
https://observatorio.fm.usp.br/handle/OPI/58295
Referências
  1. Amulic B, 2012, ANNU REV IMMUNOL, V30, P459, DOI 10.1146/annurev-immunol-020711-074942
  2. [Anonymous], 2020, Antifungal resistance j fungal diseases j CDC [Internet]
  3. Bautista-Hernández LA, 2017, EUR J MICROBIOL IMMU, V7, P151, DOI 10.1556/1886.2017.00009
  4. Reales-Calderón JA, 2014, PROTEOMICS, V14, P1503, DOI 10.1002/pmic.201300508
  5. Arts RJW, 2016, CELL METAB, V24, P807, DOI 10.1016/j.cmet.2016.10.008
  6. Arts RJW, 2016, CELL REP, V17, P2562, DOI 10.1016/j.celrep.2016.11.011
  7. Becker KL, 2015, SEMIN IMMUNOPATHOL, V37, P107, DOI 10.1007/s00281-014-0467-z
  8. Bekkering S, 2018, CELL, V172, P135, DOI 10.1016/j.cell.2017.11.025
  9. Bekkering S, 2015, CLIN THER, V37, P914, DOI 10.1016/j.clinthera.2015.01.008
  10. Blanpain C, 2014, SCIENCE, V344, P1243, DOI 10.1126/science.1242281
  11. Boutet MA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061257
  12. Braegelmann J, 2018, J EUR ACAD DERMATOL, V32, pE403, DOI 10.1111/jdv.14994
  13. Buhl AL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01162
  14. Burstein VL., 2020, Front Immunol, V11, P3143
  15. Campbell KS, 2013, J ALLERGY CLIN IMMUN, V132, P536, DOI 10.1016/j.jaci.2013.07.006
  16. Cheng SC, 2014, SCIENCE, V345, P1579, DOI 10.1126/science.1250684
  17. Ciarlo E, 2020, J INFECT DIS, V222, P1869, DOI 10.1093/infdis/jiz692
  18. Coates M, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007353
  19. Conrath U, 2006, MOL PLANT MICROBE IN, V19, P1062, DOI 10.1094/MPMI-19-1062
  20. de Hoog S, 2017, MICROBIOL SPECTR, V5, DOI 10.1128/microbiolspec.FUNK-0049-2016
  21. de Jong MAWP, 2010, MOL IMMUNOL, V47, P1216, DOI 10.1016/j.molimm.2009.12.016
  22. Debeer S, 2013, EUR J DERMATOL, V23, P456, DOI 10.1684/ejd.2013.2060
  23. Drummond RA, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a019620
  24. Duggan S, 2015, CELL MICROBIOL, V17, P1259, DOI 10.1111/cmi.12443
  25. Edgar L, 2021, CIRCULATION, V144, P961, DOI 10.1161/CIRCULATIONAHA.120.046464
  26. Eyerich S, 2011, EUR J IMMUNOL, V41, P1894, DOI 10.1002/eji.201041197
  27. Faustman DL, 2022, CELL REP MED, V3, DOI 10.1016/j.xcrm.2022.100728
  28. Gremiao IDF, 2020, EMERG INFECT DIS, V26, P621, DOI 10.3201/eid2603.190803
  29. Finethy R, 2015, INFECT IMMUN, V83, P4740, DOI 10.1128/IAI.00856-15
  30. Fisher MC, 2018, SCIENCE, V360, P739, DOI 10.1126/science.aap7999
  31. Gangishetti U, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-77380-9
  32. Garly ML, 2003, VACCINE, V21, P2782, DOI 10.1016/S0264-410X(03)00181-6
  33. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators, 2017, Lancet, V390, P1211, DOI 10.1016/S0140-6736(17)32154-2
  34. Gupta AK, 2022, J DERMATOL TREAT, V33, P1888, DOI 10.1080/09546634.2021.1942421
  35. Hamada A, 2019, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.03225
  36. Havlickova B, 2008, MYCOSES, V51, P2, DOI 10.1111/j.1439-0507.2008.01606.x
  37. Hay RJ., 2020, Hunter's Tropical Medicine and Emerging Infectious Diseases, V10th, P653
  38. Igyártó BZ, 2011, IMMUNITY, V35, P260, DOI 10.1016/j.immuni.2011.06.005
  39. Johnson CJ, 2018, MBIO, V9, DOI [10.1128/mBio.01403-18, 10.1128/mbio.01403-18]
  40. Kashem SW, 2015, IMMUNITY, V42, P356, DOI 10.1016/j.immuni.2015.01.008
  41. Kierans SJ, 2021, J PHYSIOL-LONDON, V599, P23, DOI 10.1113/JP280572
  42. Kischkel B, 2022, CELL IMMUNOL, V378, DOI 10.1016/j.cellimm.2022.104555
  43. Kischkel B, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00463
  44. Koh XQ, 2023, AUSTRALAS J DERMATOL, V64, P315, DOI 10.1111/ajd.14115
  45. Kühbacher A, 2017, MICROORGANISMS, V5, DOI 10.3390/microorganisms5020032
  46. Kühbacher A, 2017, J INFECT DIS, V215, P1742, DOI 10.1093/infdis/jix153
  47. Kurtz J, 2003, NATURE, V425, P37, DOI 10.1038/425037a
  48. Kusuhara M, 2014, J DERMATOL, V41, P386, DOI 10.1111/1346-8138.12472
  49. Lai Yuping, 2008, Infectious Disorders - Drug Targets, V8, P144
  50. Larsen SB, 2021, CELL STEM CELL, V28, P1758, DOI 10.1016/j.stem.2021.07.001
  51. Li M, 2012, J DERMATOL SCI, V66, P80, DOI 10.1016/j.jdermsci.2012.01.003
  52. Li M, 2009, EXP DERMATOL, V18, P603, DOI 10.1111/j.1600-0625.2008.00832.x
  53. Li SS, 2013, CELL HOST MICROBE, V14, P387, DOI 10.1016/j.chom.2013.09.007
  54. Lionakis MS, 2018, ANNU REV IMMUNOL, V36, P157, DOI 10.1146/annurev-immunol-042617-053318
  55. Luna E, 2012, PLANT SIGNAL BEHAV, V7, P615, DOI 10.4161/psb.20155
  56. Lyra MR, 2021, AN BRAS DERMATOL, V96, P231, DOI 10.1016/j.abd.2020.04.013
  57. Macleod T, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108515
  58. Martin SJ, 2016, FEBS J, V283, P2599, DOI 10.1111/febs.13775
  59. Mehrmal S, 2020, J AM ACAD DERMATOL, V82, P258, DOI 10.1016/j.jaad.2019.09.066
  60. Mercurio L, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0222969
  61. Merkhofer RM, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00069
  62. Mitroulis I, 2018, CELL, V172, P147, DOI 10.1016/j.cell.2017.11.034
  63. Moorlag SJCFM, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108387
  64. Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
  65. Murrieta-Coxca JM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071649
  66. Naik S, 2017, NATURE, V550, P475, DOI 10.1038/nature24271
  67. Nestle FO, 2009, NAT REV IMMUNOL, V9, P679, DOI 10.1038/nri2622
  68. Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6
  69. Netea MG, 2017, CELL HOST MICROBE, V21, P297, DOI 10.1016/j.chom.2017.02.003
  70. Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098
  71. Netea MG, 2015, NAT REV IMMUNOL, V15, P630, DOI 10.1038/nri3897
  72. Neves GWP., 2021, Front Immunol, V12, P4763
  73. Pathakumari B, 2020, BIOMED PHARMACOTHER, V130, DOI 10.1016/j.biopha.2020.110550
  74. Queiroz-Telles F, 2017, CLIN MICROBIOL REV, V30, P233, DOI 10.1128/CMR.00032-16
  75. Rizzetto L, 2016, J BIOL CHEM, V291, P7961, DOI 10.1074/jbc.M115.699645
  76. Romani L, 2007, EXPERT REV ANTI-INFE, V5, P1007, DOI 10.1586/14787210.5.6.1007
  77. Sadd BM, 2006, CURR BIOL, V16, P1206, DOI 10.1016/j.cub.2006.04.047
  78. Sahni Kanika, 2018, Indian Dermatol Online J, V9, P149, DOI 10.4103/idoj.IDOJ_281_17
  79. Salazar F, 2018, J INNATE IMMUN, V10, P373, DOI 10.1159/000488539
  80. Salazar F, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00356
  81. Sawada Y, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115794
  82. Scorzoni L, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00036
  83. Segal E, 2018, J FUNGI, V4, DOI 10.3390/jof4040135
  84. Seth D, 2017, CURR DERMATOL REP, V6, P204, DOI 10.1007/s13671-017-0192-7
  85. Shaw D, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.01964-19
  86. Quaresma JAS, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00034-18
  87. Singh B, 2012, FEMS MICROBIOL REV, V36, P1122, DOI 10.1111/j.1574-6976.2012.00340.x
  88. Stensballe LG, 2005, VACCINE, V23, P1251, DOI 10.1016/j.vaccine.2004.09.006
  89. Sullivan GP, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0385-4
  90. Tay SS, 2014, CURR DERMATOL REP, V3, P13, DOI 10.1007/s13671-013-0063-9
  91. Taylor PR, 2014, NAT IMMUNOL, V15, P143, DOI 10.1038/ni.2797
  92. Teufel LU, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24032311
  93. Thompson GR, 2021, LANCET INFECT DIS, V21, pE364, DOI 10.1016/S1473-3099(21)00191-2
  94. Urban CF, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000639
  95. Voigt J, 2014, J INFECT DIS, V209, P616, DOI 10.1093/infdis/jit574
  96. Wang Z, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.789274
  97. Wickes BL, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.01345-19
  98. Wu WW, 2016, MYCOPATHOLOGIA, V181, P631, DOI 10.1007/s11046-016-0029-0
  99. Zhao SN, 2022, EXP DERMATOL, V31, P1330, DOI 10.1111/exd.14580

Coleções
Artigos e Materiais de Revistas Científicas - LIM/53
Carregar mais